rs751505742

Variant summary

Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2

The NM_002047.4(GARS1):​c.450T>A​(p.Phe150Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: not found (cov: 32)

Consequence

GARS1
NM_002047.4 missense

Scores

3
8
7

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 0.200
Variant links:
Genes affected
GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 2 ACMG points.

PM2
Very rare variant in population databases, with high coverage;

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
GARS1NM_002047.4 linkuse as main transcriptc.450T>A p.Phe150Leu missense_variant 4/17 ENST00000389266.8 NP_002038.2 P41250-1
GARS1NM_001316772.1 linkuse as main transcriptc.288T>A p.Phe96Leu missense_variant 4/17 NP_001303701.1 P41250-2

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
GARS1ENST00000389266.8 linkuse as main transcriptc.450T>A p.Phe150Leu missense_variant 4/171 NM_002047.4 ENSP00000373918.3 P41250-1
GARS1ENST00000675651.1 linkuse as main transcriptc.450T>A p.Phe150Leu missense_variant 4/17 ENSP00000502513.1 A0A6Q8PGZ8
GARS1ENST00000675810.1 linkuse as main transcriptc.348T>A p.Phe116Leu missense_variant 3/16 ENSP00000502743.1 A0A6Q8PHH9
GARS1ENST00000675693.1 linkuse as main transcriptc.282T>A p.Phe94Leu missense_variant 5/18 ENSP00000502174.1 A0A6Q8PGA8
GARS1ENST00000675051.1 linkuse as main transcriptc.249T>A p.Phe83Leu missense_variant 4/17 ENSP00000502296.1 A0A6Q8PGI6
GARS1ENST00000674815.1 linkuse as main transcriptc.81T>A p.Phe27Leu missense_variant 4/17 ENSP00000502799.1 A0A6Q8PGW4
GARS1ENST00000674851.1 linkuse as main transcriptc.81T>A p.Phe27Leu missense_variant 5/18 ENSP00000502451.1 A0A6Q8PGW4
GARS1ENST00000444666.6 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/183 ENSP00000415447.2 H7C443
GARS1ENST00000674616.1 linkuse as main transcriptn.*164T>A non_coding_transcript_exon_variant 5/18 ENSP00000502408.1 A0A6Q8PGT3
GARS1ENST00000674643.1 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/17 ENSP00000501636.1 A0A6Q8PF45
GARS1ENST00000674737.1 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/18 ENSP00000502464.1 A0A6Q8PGZ9
GARS1ENST00000674807.1 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/16 ENSP00000502814.1 A0A6Q8PFZ6
GARS1ENST00000675529.1 linkuse as main transcriptn.*320T>A non_coding_transcript_exon_variant 5/18 ENSP00000501655.1 A0A6Q8PFN0
GARS1ENST00000675859.1 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/15 ENSP00000502033.1 A0A6Q8PFZ6
GARS1ENST00000676088.1 linkuse as main transcriptn.*320T>A non_coding_transcript_exon_variant 5/19 ENSP00000501884.1 A0A6Q8PFN0
GARS1ENST00000676140.1 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/17 ENSP00000502571.1 A0A6Q8PH49
GARS1ENST00000676164.1 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/17 ENSP00000501986.1 A0A6Q8PFV5
GARS1ENST00000676210.1 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/18 ENSP00000502373.1 A0A6Q8PGN7
GARS1ENST00000676403.1 linkuse as main transcriptn.450T>A non_coding_transcript_exon_variant 4/16 ENSP00000502681.1 A0A6Q8PHI7
GARS1ENST00000674616.1 linkuse as main transcriptn.*164T>A 3_prime_UTR_variant 5/18 ENSP00000502408.1 A0A6Q8PGT3
GARS1ENST00000675529.1 linkuse as main transcriptn.*320T>A 3_prime_UTR_variant 5/18 ENSP00000501655.1 A0A6Q8PFN0
GARS1ENST00000676088.1 linkuse as main transcriptn.*320T>A 3_prime_UTR_variant 5/19 ENSP00000501884.1 A0A6Q8PFN0
GARS1ENST00000676259.1 linkuse as main transcriptn.428-48T>A intron_variant ENSP00000501980.1 A0A6Q8PFU7

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
30
GnomAD4 genome
Cov.:
32
Bravo
AF:
0.00000756

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

Charcot-Marie-Tooth disease type 2 Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 29, 2018This variant is not present in population databases (ExAC no frequency). This sequence change replaces phenylalanine with leucine at codon 150 of the GARS protein (p.Phe150Leu). The phenylalanine residue is highly conserved and there is a small physicochemical difference between phenylalanine and leucine. This variant has not been reported in the literature in individuals with GARS-related disease. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The leucine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.91
BayesDel_addAF
Uncertain
0.025
T
BayesDel_noAF
Benign
-0.20
CADD
Benign
20
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.69
D
Eigen
Benign
-0.42
Eigen_PC
Benign
-0.29
FATHMM_MKL
Uncertain
0.91
D
LIST_S2
Uncertain
0.92
D
M_CAP
Benign
0.039
D
MetaRNN
Uncertain
0.51
D
MetaSVM
Benign
-0.89
T
PrimateAI
Pathogenic
0.89
D
PROVEAN
Pathogenic
-5.5
D
REVEL
Uncertain
0.42
Sift
Uncertain
0.025
D
Sift4G
Benign
0.14
T
Polyphen
0.0070
B
Vest4
0.48
MutPred
0.74
Loss of catalytic residue at F150 (P = 0.0622);
MVP
0.50
MPC
0.41
ClinPred
0.91
D
GERP RS
0.043
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.87
gMVP
0.81

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.060
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs751505742; hg19: chr7-30640697; API